In a recent study on recurrent or metastatic CSCC, the objective response rate was only 14.3% after treatment with anti-PD-1 antibodies for the blockade of immune checkpoints despite the selection of patients based on high PD-L1 expression score [35]. This evidence concerns the gene PDCD1 and skin squamous cell carcinoma.